Showing results (381-390 of 494) with videos related to
Sort By:
Pageof 50
The Lancet. Oncology|March 13, 2017
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Dirk Schadendorf, Paolo A Ascierto, et al.The Lancet. Oncology|August 15, 2024
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trialEmanuel Bührer, Michal Kicinski, Mario Mandala, et al.European Journal of Cancer (Oxford, England : 1990)|December 24, 2018
An open-label, multicentre safety study of vemurafenib in patients with BRAFV600-mutant metastatic melanoma: final analysis and a validated prognostic scoring systemJames Larkin, Michael P Brown, Ana M Arance, et al.European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Health-related quality of life results from the phase III CheckMate 067 studyDirk Schadendorf, James Larkin, Jedd Wolchok, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 12, 2025
Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 PatientsTakami Sato, Marcus O Butler, Sophie Piperno-Neumann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2017
Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors: Long-Term Analysis of the European Organisation for Research and Treatment of Cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose LevelsPaolo G Casali, John Zalcberg, Axel Le Cesne, et al.Insights Into Imaging|June 14, 2025
Diagnostic work-up of lipomatous tumors: a decision-making analysis among European sarcoma centersAli Naimi, Paul Martin Putora, Christian Rothermundt, et al.The Lancet. Oncology|February 16, 2026
Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 studyReinhard Dummer, Jun Guo, Jason J Luke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 7, 2024
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 StudyJason J Luke, Paolo A Ascierto, Muhammad A Khattak, et al.The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.Pageof 50